Search company, investor...
Kiadis Pharma company logo

Kiadis Pharma

Founded Year



Acq - P2P | Acquired

Total Raised




About Kiadis Pharma

Kiadis Pharma is a clinical-stage biopharmaceutical company developing potentially life-saving therapies for patients with late-stage blood cancers and related disorders, an area of significant unmet medical need. ATIR is a cell-based medicinal product candidate enabling stem cell transplantations from mismatched (haploidentical) family donors to patients suffering from blood cancer. Stem cell transplantation is the only potentially curative option for many patients but a matching donor is available for only half of the patients in need. ATIR thus has the potential to address this unmet need and to make stem cell transplantations available for patients worldwide.

Headquarters Location

Paasheuvelweg 25A

Amsterdam, 1105,


+31 (0)20 240 52 50

Missing: Kiadis Pharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Kiadis Pharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Kiadis Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Kiadis Pharma is included in 3 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Kiadis Pharma Patents

Kiadis Pharma has filed 3 patents.

patents chart

Application Date

Grant Date


Related Topics




Clusters of differentiation, Immunology, Immune system, Transcription factors, Stem cells


Application Date


Grant Date



Related Topics

Clusters of differentiation, Immunology, Immune system, Transcription factors, Stem cells



Latest Kiadis Pharma News

Global Cancer Immunotherapy Market to Surpass US$ 216,792.7 Million by 2030, Says Coherent Market Insights (CMI)

Jan 23, 2023

Pune, INDIA Burlingame, Jan. 23, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, Global Cancer Immunotherapy Market is estimated to be valued at US$ 102,095.5 million in 2022 and is expected to exhibit a CAGR of 9.9% during the forecast period (2022-2030). Analyst Views: The cancer immunotherapy market's growth can be hindered by the presence of alternative treatment methods for cancer, such as CAR T- cell therapy, oncolytic virus therapy, cancer vaccine, acupuncture, yoga, and others. For instance, data published on March 21, 2022, by National Cancer Institute, stated that there are different types of complementary and alternative medicines to treat or manage cancer such as Mind–body therapies, biologically- based practices, manipulative and body-based practices, energy healing, and others. Key Trends and Analysis of the Global Cancer Immunotherapy Market: Increasing adoption of inorganic strategies such as acquisitions between the key market players, to increase their product portfolio and presence in the market, is expected to drive the market growth over the forecast period. For instance, in August 2021, Pfizer, a pharmaceutical company announced the acquisition of Trillium, a clinical-stage immuno-oncology company, to strengthen Pfizer’s next-generation, investigational immuno-therapeutics pipeline for hematological malignancies. Driver: Increase in the prevalence of cancer Increasing global prevalence of cancer is expected to drive the growth of the market over the forecast period. For instance, data published in March 2021, on the Globocan, stated that globally there were approximately 2,261,419 cases of breast cancer and 1,931,590 cases of colorectal cancer in 2020. Increase in the adoption of organic strategies such as product approval Increasing adoption of strategies such as product approvals by the regulatory bodies is expected to drive the growth of the market over the forecast period. For instance, on February 28, 2022, Janssen Pharmaceutical Company, announced that the U.S. Food and Drug Administration (FDA) had approved CARVYKTI, which is a CAR-T immunotherapy for the treatment of patients with relapsed or refractory multiple myeloma. Request Sample copy of this Report @ Restraints: Side Effects of Cancer treatment Side effects of cancer treatment is expected to hinder growth of the cancer immunotherapy market. For instance, side effects of cancer immunotherapy includes arthritis, hypopituitarism, hypothyroidism, muscle aches, hepatitis, type 1 diabetes, neuropathy, paralysis, meningitis, or encephalitis, and others. Market Trends: Increase in the adoption of strategies such as product approval Increase in the adoption of organic strategies such as product approvals by the regulatory bodies is expected to drive the growth of the market over the forecast period. For instance, on January 20, 2022, Palleon Pharmaceuticals, a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, announced that the U.S. Food and Drug Administration had cleared the company’s investigational new drug (IND) application for its lead candidate E-602. This clearance paves the way for Palleon’s first-in-class cancer immunotherapy which targets immunosuppressive sialoglycans to enter clinical testing. Increasing initiatives by the key players in the market and government Increasing in the initiatives by the key players and government to help patients with cancer is expected to drive the growth of the market over the forecast period. For instance, in January 2021, The Lung Ambition Alliance, a global coalition with the bold ambition to eliminate lung cancer as a cause of death, started ‘The Initiatives in Lung Cancer Care (ILC2) program’. The aim of the program is to fund projects that drive measurable improvements across the patient journey, starting from early detection to palliative care or survivorship. Global Cancer Immunotherapy Market Cross Sectional Analysis: In therapy type, monoclonal antibodies segment is expected to hold a dominant position in North America region over the forecast period, due to the increasing collaboration by the key market players. For instance, on March 16, 2022, Sanofi, a pharmaceutical company, announced collaboration with Seagen Inc, a pharmaceutical company, to design, develop, and commercialize Antibody-Drug Conjugates (ADCs) up to three cancer targets. This collaboration will utilize Sanofi’s proprietary monoclonal antibody (mAb) technology and Seagen’s proprietary ADC technology. ADCs are antibodies that are engineered to deliver potent anti-cancer drugs to tumor cells, expressing a specific protein. Sanofi currently has only one ADC in development. In application segment, breast cancer segment, is expected to hold a dominant position in North America region due to increasing prevalence of breast cancer in the region. For instance, data published on May 10, 2022, by National Cancer Institute, stated that in the U.S. there were approximately 290,560 new breast cancer cases in 2022. Key Developments: In June 2020, Genmab, a pharmaceutical company, announced collaboration with AbbVie Inc., a pharmaceutical company, to jointly develop and commercialize three of Genmab’s early-stage investigational bispecific antibody product candidates and enter into a discovery research collaboration for future differentiated antibody therapeutics for cancer. The companies collaborated to develop Genmab’s next-generation bispecific antibody programs, epcoritamab DuoHexaBody-CD37 and DuoBody-CD3x5T4. This collaboration combined Genmab’s world-class discovery and development engine and next-generation bispecific antibody therapeutic candidates with AbbVie’s deep clinical expertise, innovative antibody-drug conjugate (ADC) platform and global commercial leadership in hematological cancers. In April 2021, the U.S. Food and Drug Administration approved Opdivo, in combination with certain types of chemotherapy, for the initial treatment of patients with advanced or metastatic gastric cancer, gastro esophageal junction cancer, and esophageal adenocarcinoma. This is the first FDA-approved immunotherapy for the first-line treatment of gastric cancer. In November 2020, Sanofi, a pharmaceutical company, announced acquisition of Kiadis Pharma, a pharmaceutical company specialized in cell-based immunotherapy products to treat cancer. The acquisition will give Sanofi access to Kiadis’ K-NK-cell platform, which is designed to make products rapidly and economically available for a broad patient population across a wide range of indication. This will strengthen Sanofi’s product portfolio. On September 9, 2022, Siemens Healthineers, a medical device company, announced partnerships with the Indian Institute of Science (IISc), which is a research university, HealthCare Global Enterprises Ltd (HCG), a healthcare organization and Narayana Health (NH), which is a multispeciality private hospital. Siemens Healthineers   will work with all the three organizations in the areas such as advancing cardiovascular care, enhancing the quality of cancer care for the community, and developing fellowship programs in the oncology space. Key Market Takeaways: The global cancer immunotherapy market is expected to exhibit a CAGR of 9.9% during the forecast period due to increasing prevalence of cancer. For instance, according to data published in May 2022, by Canadian Cancer Society, which is Canada's national cancer charity organization, estimated that 30,000 Canadians will be diagnosed with lung and bronchus cancer in 2022. Among application, breast cancer segment is expected to hold a dominant position over the forecast period due to the increase in the awareness initiatives by the key players in the market. For instance, on October 22, 2022, Urban Company, tech-enabled home services company, tied up with HCG Cancer Chain of Hospitals. As a part of this initiative, oncologists from HCG conducted workshops on self-breast-examination to create an awareness on breast cancer. On the basis of end user, hospital segment is expected to hold a dominant position over the forecast period due to increase in the number of hospitals. For instance, data published in January 2022, by American Hospital Association, stated that in the U.S. there were approximately 6,093 hospitals in 2022. Competitive Landscape: Key players operating in the global cancer immunotherapy market include Novartis AG, Merck & Co. Inc., F-Hoffmann La Roche, Eli Lilly and Company, Bayer AG, AstraZeneca, Astellas Pharma Inc., Amgen Inc., OSE Immunotherapeutics SA, and Bristol- Myers Squibb Company Buy-Now this Research Report @ Market Segmentation: Monoclonal Antibodies Prostate Cancer Hospitals and Clinics North America

Kiadis Pharma Frequently Asked Questions (FAQ)

  • When was Kiadis Pharma founded?

    Kiadis Pharma was founded in 1997.

  • Where is Kiadis Pharma's headquarters?

    Kiadis Pharma's headquarters is located at Paasheuvelweg 25A, Amsterdam.

  • What is Kiadis Pharma's latest funding round?

    Kiadis Pharma's latest funding round is Acq - P2P.

  • How much did Kiadis Pharma raise?

    Kiadis Pharma raised a total of $36.9M.

  • Who are the investors of Kiadis Pharma?

    Investors of Kiadis Pharma include Sanofi, EQT Life Sciences, Agentschap, Quest for Growth, Nom Labs and 11 more.

  • Who are Kiadis Pharma's competitors?

    Competitors of Kiadis Pharma include Alpex Pharma, Cornerstone Pharmaceuticals, Viracta Therapeutics, Xhale, Neuraltus Pharmaceuticals, Santaris Pharma, SpiroGen, Onconova Therapeutics, Aldagen, Novalar Pharmaceuticals and 13 more.

Compare Kiadis Pharma to Competitors

Marillion Pharmaceuticals

Marillion Pharmaceuticals, Inc. - Marillion is developing clinical-stage drugs in oncology and oncology supportive care. 177Lu-AMBA is a targeted radiotherapeutic, with the low level radiation of lutetium that aims to utilize an receptor-based technology, and can serve as both a diagnostic and therapeutic agent. The targeting capability means that 177Lu-AMBA homes in on tumor cells and spares normal tissues. 177Lu-AMBA is being pursued initially to treat hormone-resistant prostate cancer, has been studied in a phase I trial in Europe. Marillion also is developing PilobucTM , buccal formulation of pilocarpine ,for the treatment of dry mouth, shown in clinical trials to effectively and conveniently deliver the drug with reduced side effects compared to other routes of administration.PilobucTM buccal formulation of pilocarpine has the potential to be a product in the xerostomia market. Marillion is preparing for phase II trials of the product candidate..

Esperance Pharmaceuticals

Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.

Activate Immunotherapy

Activate Immunotherapy (formerly NovaRx) is a clinical-stage immuno-oncology company based in San Diego, California. Activate utilizes a novel approach for activating the body's immune system to recognize and destroy cancer cells. The company's most advanced immunotherapy, Lucanix, has been tested in late stage clinical trials as a treatment for non-small cell lung cancer (NSCLC), the largest cancer indication in the world. Lucanix has promising Phase 2 and Phase 3 data. In Lucanix's Phase 2 trial, the company demonstrated a significant improvement in survival for NSCLC patients. NovaRx completed a 532 patient Phase 3 study in early 2013. While the Phase 3 study missed the statistical endpoint for approval, survival benefits were shown if non United States clinical sites were excluded, particularly with patients who started Lucanix treatment within 12 weeks of chemotherapy and/or patients with prior chemotherapy and radiation therapy. Activate's proprietary platform technology is applicable to other solid tumors.


Unibioscreen is a specialist oncology discovery & development company, with focus on 'first in class' drugs, mainly of natural origin. Unibioscreen has successfully developed 2 drug candidates from discovery to clinical development in cancer patients and has other promising pre-clinical compounds in its pipeline.

Endotis Pharma

Endotis Pharma is A specialty discovery and development company developing small glycol drugs for thrombosis and oncology


Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.